Immunomodulatory Activity of Nivolumab in Metastatic Renal Cell Carcinoma

PURPOSE: Nivolumab, an anti-PD-1 immune checkpoint inhibitor, improved overall survival versus everolimus in a phase 3 trial of previously treated patients with metastatic renal cell carcinoma (mRCC). We investigated immunomodulatory activity of nivolumab in a hypothesis-generating prospective mRCC...

Description complète

Enregistré dans:
Détails bibliographiques
Publié dans:Clin Cancer Res
Auteurs principaux: Choueiri, Toni K., Fishman, Mayer N., Escudier, Bernard, McDermott, David F., Drake, Charles G., Kluger, Harriet, Stadler, Walter M., Perez-Gracia, Jose Luis, McNeel, Douglas G., Curti, Brendan, Harrison, Michael R., Plimack, Elizabeth R., Appleman, Leonard, Fong, Lawrence, Albiges, Laurence, Cohen, Lewis, Young, Tina C., Chasalow, Scott D., Ross-Macdonald, Petra, Srivastava, Shivani, Jure-Kunkel, Maria, Kurland, John F., Simon, Jason S., Sznol, Mario
Format: Artigo
Langue:Inglês
Publié: 2016
Sujets:
Article
Accès en ligne:https://ncbi.nlm.nih.gov/pmc/articles/PMC5106340/
https://ncbi.nlm.nih.gov/pubmed/27169994
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/1078-0432.CCR-15-2839
Tags: Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!

Documents similaires